{"version":"1.0","provider_name":"Kuwait News Gazette","provider_url":"https:\/\/kuwaitnewsgazette.com","author_name":"kgadmin","author_url":"https:\/\/kuwaitnewsgazette.com\/author\/kgadmin\/","title":"FDA Approves Genio\u00ae 2.1 For Use in DREAM U.S. IDE Pivotal Study - Kuwait News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ednylLNaQg\"><a href=\"https:\/\/kuwaitnewsgazette.com\/fda-approves-genio-2-1-for-use-in-dream-u-s-ide-pivotal-study\/\">FDA Approves Genio\u00ae 2.1 For Use in DREAM U.S. IDE Pivotal Study<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kuwaitnewsgazette.com\/fda-approves-genio-2-1-for-use-in-dream-u-s-ide-pivotal-study\/embed\/#?secret=ednylLNaQg\" width=\"600\" height=\"338\" title=\"&#8220;FDA Approves Genio\u00ae 2.1 For Use in DREAM U.S. IDE Pivotal Study&#8221; &#8212; Kuwait News Gazette\" data-secret=\"ednylLNaQg\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"FDA Approves Genio\u00ae 2.1 For Use in DREAM U.S. IDE Pivotal Study\u00a0 New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium \u2013 June 1, 2022, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/QEj66wipowIwihEqcTYaeT9jGb_3vsY9YvI4ng_lnWNEpMESWxa9865QIKM27vZvMnvT8YHZBVFQREQVGMTQYo-OC3TMvNhlnkToQeLcGxXY5-ioeRfmeh4S5Kk3ofGevSMb7wJo3CI=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDY1NjkwMCM0MDEyNjM4MTMjMjE5NzYyNw=="}